Skip to main content
PLX
NYSE Life Sciences

Protalix Q3 2026: Net Income $4.0M, YTD Revenue $75.6M, 2026 Guidance Reaffirmed

Arie Shkolnikov · Analysis by Wiseek AI
Sentiment info
Positive
Importance info
7
Price
$2.71
Mkt Cap
$207.069M
52W Low
$1.65
52W High
$3.19
52W Position info
64% above low
Off High info
15% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

PLX sits 64% above its 52-week low of $1.65.

Summary

Protalix reported Q3 2026 net income of $4.0 million and $75.6 million of year-to-date revenue, reaffirming 2026 guidance of $78.0 million to $83.0 million with $48.5 million in cash and no debt or warrants.


Key Events · Earnings and Guidance · PLX

  • Q3 Profit and YTD Revenue Jump

    Q3 2026 net income was $4.0 million, or $0.05 per share, versus $2.4 million a year earlier. Nine-month revenue reached $75.6 million, up $32.0 million from $43.6 million, including a $25.0 million Chiesi milestone.

  • 2026 Guidance Reaffirmed

    Management expects to meet or exceed 2026 total revenue of approximately $78.0 million to $83.0 million, including Elfabrio sales of $33.0 million to $35.0 million and Elelyso sales of $20.0 million to $23.0 million.

  • Balance Sheet: $48.5M Cash, No Debt

    Cash, cash equivalents and short-term bank deposits were $48.5 million at September 30, 2026, and the company states it has no outstanding debt or warrants.

  • PRX-115 Data Not Until H2 2027

    The Phase 2 RELEASE study in uncontrolled gout continues enrolling; top-line results are anticipated in the second half of 2027, leaving near-term performance dependent on product sales.


Analysis · PLX · Life Sciences

Protalix swung to a nine-month profit of $26.1 million from a $1.1 million loss a year earlier, driven by $75.6 million of year-to-date revenue that includes a $25.0 million Chiesi milestone. Management reaffirmed 2026 revenue guidance of roughly $78.0 million to $83.0 million and said it expects to meet or exceed that range, while holding $48.5 million in cash and deposits and carrying no debt or warrants. The remaining value driver is PRX-115 in uncontrolled gout, where Phase 2 RELEASE enrollment continues and top-line data are not expected until the second half of 2027 — so near-term results rest on Elfabrio and Elelyso product sales.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PLX was trading at $2.71 on NYSE in the Life Sciences sector, with a market capitalization of approximately $207.1M. The 52-week trading range was $1.65 to $3.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PLX - Latest Insights